Latest acquisition is Reglera, leading consulting firm for med devices and human tissue products
Cynthia LaConte, the acquisitive CEO of Dohmen Group (Milwaukee) has struck again: its sixth acquisition in the past two years is Reglera (Wheat Ridge, CO), which provides a range of outsourcing services to device and tissue developers. From its base as a logistics service provider to manufacturers, and a consulting and benefit-management firm to insurers, the company has now expanded into medical affairs, orphan-drug distribution, pharmacovigilance and safety training, and medical communications. Now it is looking to apply those same skill sets to the med device world.
For its part, Reglera provides a range of outsourced services, including quality control and document management (both for regulatory submissions and commercial operations), product development consulting, adverse event reporting, contract manufacturing and fulfillment, among others. “With over 500 clients we’ve worked with, we’ve seen it all, from the physician-entrepreneur to the largest med-device manufacturers around,” says CEO Clay Anselmo.
“As personalized medicine becomes an increasingly viable healthcare model, traditional lines between pharma, bio, tissue and devices begin to blur. Expanding our medical device capability became the next logical step in our strategic plan to provide a holistic suite of support services to Life Science companies that are making the transition to therapeutic care companies,” said LaConte.
Like its new parent, Reglera shares a “conflict free” business philosophy, according to Anselmo: The company delivers its work on a fee-for-service basis, not taking ownership of the products and staying apart from financial incentives from buyers. Potential synergies with the rest of the Dohmen organization—such as handling product distribution through Dohmen’s DDN Pharmaceutical Logistics unit—remain to be worked out.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.